Drug Trial Radar · NCT07003074
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
642
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Jul 2029
Study completion Jul 2030
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Conditions
- Breast Cancer
Interventions
TQB2102 for InjectionDrug
TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer.
Docetaxel combined + Trastuzumab +PertuzumabDrug
Positive control.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Up to approximately 30 months
- Progression-Free SurvivalTime frame: Up to approximately 30 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Shantou Central Hospital
Shantou, Guangdong, China · Not yet recruiting
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Not yet recruiting
Huaihe Hospital of Henan University
Kaifeng, Henan, China · Not yet recruiting
Puyang Oilfield General Hospital
Puyang, Henan, China · Not yet recruiting
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Affiliated Zhongshan Hospital Of Dalian University
Dalian, Liaoning, China · Not yet recruiting
Affiliated Zhongshan Hospital Of Dalian University
Dalian, Liaoning, China · Not yet recruiting
Liaoning Provincial Cancer Hospital
Shenyang, Liaoning, China · Not yet recruiting
The First Affiliated Hospital of Xi'An Jiaoting Yniversity
Xi'an, Shaanxi, China · Not yet recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Fudan University shanghai cancer center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Yuncheng Central Hospital, Shanxi Province
Yuncheng, Shanxi, China · Not yet recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
The Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.